Branched-chain amino acids attenuate early kidney injury in diabetic rats

Na Mi1, Xiu Juan Zhang2, Yan Ding3

  • 1Department of Endocrinology, Shandong Provincial Hospital affiliated with Shandong University, China; Department of Endocrinology, The Third Hospital of Jinan, Shandong, China.

Insights

Branched-chain amino acids (BCAAs) reduce kidney oxidative stress and injury in diabetic rats. This study shows BCAAs can prevent early diabetic nephropathy by targeting the JNK/TGF-β/MMP-9 pathway.

Area of Science:

  • Nephrology
  • Endocrinology
  • Biochemistry

Background:

  • Diabetic nephropathy (DN) is a severe complication of diabetes, characterized by oxidative stress.
  • Reactive oxygen species (ROS) contribute to DN pathogenesis by activating signaling pathways like TGF-β and MMP-9, leading to glomerular hypertrophy.
  • Branched-chain amino acids (BCAAs) have shown potential in reducing oxidative stress in diabetic conditions affecting the pancreas and liver.

Purpose of the Study:

  • To investigate if BCAAs can mitigate oxidative stress in the kidneys of streptozotocin (STZ)-induced diabetic rats.
  • To determine if BCAA administration can prevent early-stage diabetic kidney injury.
  • To elucidate the role of the JNK/TGF-β/MMP-9 pathway in BCAA's protective effects against diabetic nephropathy.

Main Methods:

  • Male Wistar rats were induced into diabetes using streptozotocin (STZ) after a high-fat diet.
  • Diabetic rats were treated with varying doses of BCAAs or vehicle for two months.
  • Measurements included plasma glucose, creatinine, urinary protein, ROS levels, and JNK, TGF-β, and MMP-9 mRNA and protein expression.

Main Results:

  • STZ-induced diabetic rats exhibited elevated ROS levels, proteinuria, and early kidney injury compared to controls.
  • BCAA treatment significantly reduced ROS levels, proteinuria, and attenuated kidney damage.
  • Diabetic rats showed increased JNK, TGF-β, and MMP-9 expression, which was reversed by BCAA administration.

Conclusions:

  • BCAAs effectively counteract kidney oxidative stress in diabetic rats.
  • BCAA treatment alleviates diabetic kidney injury by inhibiting the JNK/TGF-β/MMP-9 signaling pathway.
  • BCAAs show promise as a therapeutic strategy for preventing or treating early diabetic nephropathy.

Related Concept Videos

Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
494
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
1.9K
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
1.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K